Skp2 antibody | knockout validation | Santa Cruz sc-7164
DOI
//dx.doi.org/10.13070/ko.en.6.1822
Date
2016-11-19

This is a knockout-validated antibody summary, based on the publication "SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Skp2 antibody | knockout validation | Santa Cruz sc-7164 figure 1
Figure 1. Western blot analysis of protein levels of Skp2 in Pten/Trp53 and Skp2/Pten/Trp53 null MEFs. From [1].
Antibody information

Rabbit polyclonal IgG

Company: Santa Cruz

Antibody: Skp2

Catalog number: sc-7164

Summary: Rabbit polyclonal IgG raised against amino acids 1-424 representing full length Skp2 p45 of human origin. Recommended for detection of Skp2 p45 of mouse, rat and human origin by western blot, immunoprecipitation, immunofluorescence, immunohistochemistry (paraffin) and ELISA. Also reactive with additional species, including and equine, canine, bovine and porcine.

Validation Method

Western blot

Sample

Pten/Trp53 and Skp2/Pten/Trp53 null MEFs. Cell lysates were prepared in RIPA buffer (1×PBS, 1% Nonidet P40/Triton X-100, 0.5% sodium deoxycholate, 2mM EDTA, with or without 0.1% SDS) with protease inhibitor cocktail (Roche).

Primary incubation

1:500 dilution.

Disclaimer

If the antibody described in this summary is a polyclonal antibody, since polyclonal antibodies are of limited quantity, please inquire the supplier whether any current polyclonal antibody with the same catalog number is exactly the same as the one described in this summary. Sometimes, different bleeds or different animals are used, usually with a different lot number. In such cases, the result in this summary may not apply to the new antibody with the same catalog number.

References
  1. Lu W, Liu S, Li B, Xie Y, Adhiambo C, Yang Q, et al. SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination. Oncotarget. 2015;6:771-88 pubmed